Property and Casualty Insurance Analysis Platform Exzeo (XZO.US) IPO priced at $21, experiences debut day post-market price drop.
The property and casualty insurance and analytics platform Exzeo Group, spun off from HCI Group, issued 8 million shares at a price of $21 per share (midpoint of the $20 to $22 range), raising $168 million.
The property and casualty insurance and analytics platform Exzeo Group, spun off from HCI Group, issued 8 million shares at a price of $21 per share (the midpoint of the $20 to $22 range), raising $168 million. Based on the pricing, Exzeo's fully diluted market value is $2 billion. On its first day of trading, Exzeo Group closed down 2.38%, at $20.51.
Exzeo provides insurance technology solutions for property and casualty underwriters and their agents through its proprietary Exzeo platform. The platform currently includes 9 software and data analytics applications that support functions such as quoting and underwriting, policy management, claims management, data and analytics, reporting, and financial management. Exzeo currently serves customers in 13 states, despite holding insurance agency or managing general agent licenses in 29 states. Its solutions support the management of over $1.2 billion in premium.
Founded in 2012, Exzeo had revenues of $182 million for the 12 months ending on June 30, 2025. The company plans to list on the New York Stock Exchange under the ticker symbol XZO. Exzeo Group submitted a confidential application on August 6, 2025. Truist Securities, Citizens JMP, and William Blair are the joint book-running managers for this transaction.
Related Articles

WEIGAO GROUP (01066) spent HK$1.8368 million on November 6 to repurchase 340,000 shares.

COSCO Shipping Holdings (01919) spent approximately HK$20.98 million on November 6th to repurchase 1.53 million shares.

Shanghai Pharmaceuticals Holding (601607.SH): Tofacitinib Citrate Extended-Release Tablets Approved for Production.
WEIGAO GROUP (01066) spent HK$1.8368 million on November 6 to repurchase 340,000 shares.

COSCO Shipping Holdings (01919) spent approximately HK$20.98 million on November 6th to repurchase 1.53 million shares.

Shanghai Pharmaceuticals Holding (601607.SH): Tofacitinib Citrate Extended-Release Tablets Approved for Production.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


